Investigation of immunohistochemistry critical assay performance controls (iCAPC) to reduce inter-observer interpretation variability of BRAF V600E.
Immunohistochemistry Critical Assay Performance Controls (iCAPC) are gold standard sets of tissue controls that robustly show strong, weak and negative expression for specified proteins, initially introduced to provide standardization and reduction of pre-analytical and analytical errors of the resp...
| Publicado en: | Canadian Journal of Pathology Vol. 9; p. 28 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Canadian Association of Pathologists
2017 Supplement
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139556706&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 139556706 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1918915X B17Q jtl: Canadian Journal of Pathology issn: 1918915X maglogo: N pubinfo: dt: 2017 Supplement vid: 9 pid: 62888 pub: Canadian Association of Pathologists place: Kingston, Ontario artinfo: ui: 139556706 139556706 ppf: 28 ppct: 0 formats: fmt: @attributes: type: P tig: atl: Investigation of immunohistochemistry critical assay performance controls (iCAPC) to reduce inter-observer interpretation variability of BRAF V600E. aug: au: Gale, Nadia Cai, Ellen Kalloger, Steve Liu, Ariel Hickey, Tyler Abozina, Alisa Derakhshan, Fatemeh Ongaro, Deidre Schaeffer, David S. affil: Vancouver Coastal Health, University of British Columbia, Vancouver, BC, Canada sug: ab: Immunohistochemistry Critical Assay Performance Controls (iCAPC) are gold standard sets of tissue controls that robustly show strong, weak and negative expression for specified proteins, initially introduced to provide standardization and reduction of pre-analytical and analytical errors of the respective immunohistochemistry (IHC) stains. Within Vancouver Coastal Health, iCAPC are incorporated for all class II antibodies including BRAF V600E. BRAF is a predictive and prognostic biomarker for cancers such as colorectal adenocarcinoma and metastatic melanoma. BRAF V600E protein detection by IHC is comparable to the gold standard polymerase chain reaction (PCR) assay. An exhaustive review yielded no previous studies evaluating the efficacy of iCAPC in reducing inter-observer interpretation variability. In this study, 173 cases with reported BRAF mutational status were collected, providing two sets of slides: routine controls (115) and iCAPC (58). One pathology resident interpreted the two slide sets. Kappa coefficients for the pathology resident's results to the previous reports were calculated: Based on this preliminary data, the use of BRAF V600E iCAPC decreases inter-observer interpretation variability. Five additional residents will review the two slide sets, with an additional 56 slides in the iCAPC set. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|